1. The interval from the onset of symptoms to the introduction of levodopa was unrelated to the time from levodopa initiation to motor complication onset. There no longer appears to be a rational basis for delaying levodopa therapy in parkinsonian patients. 2. Motor response complications reflect striatal system changes due to dopaminergic deafferentation and intermittent dopaminomimetic treatment and tend to normalize with the more physiologic stimulation afforded by continuous replacement strategies. 3. Glutamatergic mechanisms affect extrapyramidal motor function: In rats, D-2 mediated responses require concurrent NMDA receptor stimulation, while D-1 receptor-regulated pathways have varying degrees of sensitivity to NMDA receptor blockade; the subthalamic nucleus contributes primarily to the expression of D-2 mediated motor behaviors. In patients with Parkinson's disease, glutamatergic stimulation with milacemide transiently increased overall parkinsonian severity, especially rigidity. 4. No generalized defect in mitochondrial respiratory function could be documented in Parkinson's disease: oxygen consumption rates and respiratory chain enzyme activities in platelets and muscle mitochondria as well as blood lactate levels following glucose loading did not differ significantly between patients and controls. 5. Tourette syndrome patients have marked decreases in ventral brain areas, increases along the superior cortical convexities, and inverted relationships between these limbic and sensorimotor cortical regions appear on PET-fluorodeoxyglucose scans. 6. Physostigmine by continuous intravenous infusion at maximum tolerated levels inhibits CSF acetylcholinesterase by only 21% and produces little cognitive benefit. Amnestic doses of the anticholinergic, scopolamine, increase cortical function in normal elderly subjects in contrast to the decreases, especially parietotemporal, in PET scans of Alzheimer patients. Physostigmine, rather than normalizing, marginally diminishes cortical metabolism.
| Aksu, Murat; Demirci, Sevda; Bara-Jimenez, William (2007) Correlation between putative indicators of primary restless legs syndrome severity. Sleep Med 8:84-9 |
| Lomarev, Mikhail P; Kanchana, Sulada; Bara-Jimenez, William et al. (2006) Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 21:325-31 |
| Fujita, Masahiro; Ichise, Masanori; Zoghbi, Sami S et al. (2006) Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59:174-7 |
| Bara-Jimenez, William; Dimitrova, Tzvetelina D; Sherzai, Abdullah et al. (2006) Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 21:1380-3 |
| Leon-Sarmiento, Fidias E; Bara-Jimenez, William; Wassermann, Eric M (2005) Visual deprivation effects on human motor cortex excitability. Neurosci Lett 389:17-20 |
| Palkovacs, Eric P; Oppenheimer, Adam J; Gladyshev, Eugene et al. (2004) Genetic evaluation of a proposed introduction: the case of the greater prairie chicken and the extinct heath hen. Mol Ecol 13:1759-69 |
| Chase, Thomas N (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 10:305-13 |
| Wessell, R H; Ahmed, S M; Menniti, F S et al. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47:184-94 |
| Andringa, G; Lam, K Y; Chegary, M et al. (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J 18:932-4 |
| Blanchet, Pierre J; Konitsiotis, Spiros; Mochizuki, Hideki et al. (2003) Complications of a trophic xenotransplant approach in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 27:607-12 |
Showing the most recent 10 out of 34 publications
